Anthracycline and Peripartum Cardiomyopathies
Authors:
- 24 May 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 124 (11) , 1633-1646
Abstract
Anthracycline-associated cardiomyopathy and peripartum cardiomyopathy are nonischemic cardiomyopathies that often afflict previously healthy young patients; both diseases have been well described since at least the 1970s and both occur in the settings of predictable stressors (ie, cancer treatment and pregnancy). Despite this, the precise mechanisms and the ability to reliably predict who exactly will go on to develop cardiomyopathy and heart failure in the face of anthracycline exposure or childbirth have proven elusive. For both cardiomyopathies, recent advances in basic and molecular sciences have illuminated the complex balance between cardiomyocyte and endothelial homeostasis via 3 broad pathways: reactive oxidative stress, interference in apoptosis/growth/metabolism, and angiogenic imbalance. These advances have already shown potential for specific, disease-altering therapies, and as our mechanistic knowledge continues to evolve, further clinical successes are expected to follow.Keywords
This publication has 152 references indexed in Scilit:
- Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control studyInternational Journal of Cardiology, 2013
- Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathyBasic Research in Cardiology, 2013
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Cardiac angiogenic imbalance leads to peripartum cardiomyopathyNature, 2012
- The development of congestive heart failure and ventricular tachycardia after first exposure to idarubicin in a patient with acute myeloid leukaemiaBritish Journal of Clinical Pharmacology, 2010
- Anthracycline-Induced CardiomyopathyJACC, 2010
- Improved outcomes in peripartum cardiomyopathy with contemporaryAmerican Heart Journal, 2006
- Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategiesBritish Journal of Haematology, 2005
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast CancerNew England Journal of Medicine, 1988